-
Celebrex Ads Return Despite Continuing Heart Risk Controversy
Celebrex DTC Advertising Was Suspended By Pfizer During 2005 At Request Of FDA Some people may have noticed recently that Pfizer Inc. is advertising its blockbuster drug Celebrex, again, in full-page color ads appearing…
-
GAO Report Says FDA’s Postmarket Drug-Safety Monitoring Is Not Effective
FDA Fails To Timely Detect Emerging Unsafe Drugs Because Of Agency Flaws And Limitations A Government Accountability Office (GAO) report released on April 24, 2006 reached the conclusion that the FDA "lacks a clear…
-
Patients Increasingly Turn To Internet for Prescription Drug Information
Doctors Are Still Most-Trusted Sources; Pharmacists and Web Sites Nearly Tied For Second Survey results released in the first part of April 2006 show that patients in the U.S. are using web sites on…
-
April 2006 FDA “Patient Safety News” Videos For Doctors Online
Edition Covers Ketek, Clozaril, Benzocaine Sprays, and More The FDA’s Patient Safety News (PSN) is a series of monthly video news shows intended primarily for doctors and other health care professionals. Generally, this series…
-
Did Merck Fail To Warn About Fosamax Side Effects?
Osteoporosis Drug Fosamax Associated With Reports Of Osteonecrosis Of Jaw Merck & Co. allegedly failed to warn doctors and patients in a timely manner about osteonecrosis of the jaw (rotting of the jaw bone),…
-
Punitive Damages Award Brings McDarby Verdict to $13.5 Million
How Did Merck Lose A Critical Vioxx Trial In New Jersey, Its "Home Court"? On April 5, 2006 the jury in John McDarby v. Merck & Co., Inc. awarded Mr. McDarby and his wife…
